Clinical Trials Logo

Advanced Malignant Solid Tumors clinical trials

View clinical trials related to Advanced Malignant Solid Tumors.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05949775 Not yet recruiting - Clinical trials for Advanced Malignant Solid Tumors

Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors

Start date: July 20, 2023
Phase: N/A
Study type: Interventional

This study is an open, single arm, dose increasing study to evaluate the safety and efficacy of the combination of mRNA personalized tumor vaccine encoding neoantigen (hereinafter referred to as tumor vaccine) and Sintilimab injection (hereinafter referred to as Sintilimab) in the treatment of advanced malignant solid tumors.

NCT ID: NCT05478785 Not yet recruiting - Clinical trials for Advanced Malignant Solid Tumors

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors

Start date: August 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label, dose-escalation, dose-expansion, and cohort-expansion Phase I/II clinical study to evaluate safety, tolerability, pharmacokinetics, antitumor efficacy and to determine the maximum tolerated dose (MTD) and recommended Phase 2 doses (RP2D) of cisplatin micelle injection in patients with advanced malignant solid tumors. This study is divided into two stages, the first stage (stage I) is the dose escalation and dose expansion study of cisplatin micelle injection, to determine the maximum tolerated dose (MTD), and to initially explore the recommended dose of phase II clinical practice (RP2D). The second stage (stage II) is the cisplatin micelle injection cohort expansion study to evaluate the efficacy and safety of cisplatin micelle injection (HA132) in patients with advanced solid tumors.

NCT ID: NCT05383703 Not yet recruiting - Clinical trials for Advanced Malignant Solid Tumors

Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor

MNC-168
Start date: June 30, 2022
Phase: Phase 1
Study type: Interventional

This study is a multicenter, open-label, dose-escalation Phase I clinical trial designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of live bacterium MNC-168 as a single oral agent in subjects with advanced malignant solid tumors. To explore the changes of biomarkers and intestinal flora related to curative effect, mechanism of action, safety and/or pathological mechanism.